COMMITMENTS AND CONTINGENCIES (Tables)

6 Months Ended

Jun. 30, 2021

Commitments and Contingencies Disclosure [Abstract]

A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the six months ended June 30, 2021 and June 30, 2020 is as follows (in thousands):


Six Months Ended June 30, 2021	Contingent Consideration Liability Related to Acquisition of:
	Arkis				Location in Financial Statements	Derma Sciences		ACell Inc. (See Note 2)		Location in Financial Statements
	Short-term		Long-term			Long-term		Long-term
Balance as of January 1, 2021	$	3,415	$	11,746		$	230	$	—
Additions from acquisition of ACell	—		—			—		23,900
Transfers	(3,432)		3,432			—		—
Gain (loss) from change in fair value of contingent consideration liabilities	17		$	(402)	Research and development	—		(400)		Selling, general and administrative
Balance as of June 30, 2021	$	—	$	14,776		$	230	$	23,500


Six Months Ended June 30, 2020	Contingent Consideration Liability Related to Acquisition of:
	Arkis		Derma Sciences		Location in Financial Statements
	Long-term		Long-term
Balance as of January 1, 2020	$	14,210	$	230





Loss from change in fair value of contingent consideration liabilities	(708)		—		Research and development
Balance as of June 30, 2020	$	13,502	$	230